Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Trippoli

Showing results (1-10 of 43) with videos related to

Pageof 5
Sort By:
Anti-Cancer Drugs|January 16, 1999
Pharmacoeconomic profile of taxanes in advanced ovarian cancerA Messori, S Trippoli
Oncology Reports|July 30, 1999
A new method for expressing survival and life expectancy in lifetime cost-effectiveness studies that evaluate cancer patients (review)A Messori, S Trippoli
Heart (British Cardiac Society)|September 30, 2009
Emerging transcatheter therapies for aortic and mitral diseaseA Messori, S Trippoli
JAMA|December 24, 1998
Cost-effectiveness analyses of statistically ineffective treatmentsS Trippoli, A Messori
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 1998
Can the Q-TWiST method provide information on patients' preferences without collecting preference data from the patients? Quality-Adjusted Time Without Symptoms or ToxicityA Messori, S Trippoli
Heart (British Cardiac Society)|April 30, 2009
Drug-eluting stents for the treatment of coronary artery disease: NICE technology appraisal guidanceA Messori, S Trippoli
Haematologica|March 21, 1998
Median versus mean lifetime survival in the analysis of survival dataA Messori, P Becagli, S Trippoli
Journal of Chemotherapy (Florence, Italy)|May 17, 2011
A uniform procedure for reimbursing the off-label use of antineoplastic drugs according to the value-for-money approachA Messori, V Fadda, S Trippoli
Annals of Internal Medicine|April 15, 1997
Cost-effectiveness of interferon-alpha as maintenance therapy in chronic myelogenous leukemiaA Messori, P Becagli, S Trippoli
Journal of Clinical Pharmacy and Therapeutics|April 1, 1996
G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluationA Messori, S Trippoli, E Tendi
Pageof 5

Showing results (1-10 of 43) with videos related to

Sort By:
Pageof 5
Anti-Cancer Drugs|January 16, 1999
Pharmacoeconomic profile of taxanes in advanced ovarian cancerA Messori, S Trippoli
Oncology Reports|July 30, 1999
A new method for expressing survival and life expectancy in lifetime cost-effectiveness studies that evaluate cancer patients (review)A Messori, S Trippoli
Heart (British Cardiac Society)|September 30, 2009
Emerging transcatheter therapies for aortic and mitral diseaseA Messori, S Trippoli
JAMA|December 24, 1998
Cost-effectiveness analyses of statistically ineffective treatmentsS Trippoli, A Messori
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 1998
Can the Q-TWiST method provide information on patients' preferences without collecting preference data from the patients? Quality-Adjusted Time Without Symptoms or ToxicityA Messori, S Trippoli
Heart (British Cardiac Society)|April 30, 2009
Drug-eluting stents for the treatment of coronary artery disease: NICE technology appraisal guidanceA Messori, S Trippoli
Haematologica|March 21, 1998
Median versus mean lifetime survival in the analysis of survival dataA Messori, P Becagli, S Trippoli
Journal of Chemotherapy (Florence, Italy)|May 17, 2011
A uniform procedure for reimbursing the off-label use of antineoplastic drugs according to the value-for-money approachA Messori, V Fadda, S Trippoli
Annals of Internal Medicine|April 15, 1997
Cost-effectiveness of interferon-alpha as maintenance therapy in chronic myelogenous leukemiaA Messori, P Becagli, S Trippoli
Journal of Clinical Pharmacy and Therapeutics|April 1, 1996
G-CSF for the prophylaxis of neutropenic fever in patients with small cell lung cancer receiving myelosuppressive antineoplastic chemotherapy: meta-analysis and pharmacoeconomic evaluationA Messori, S Trippoli, E Tendi
Pageof 5